2,400 people remain without rare disease drug as Takeda manufacturing woes continue
Since September 2019, 2,400 people with the rare condition known as hypoparathyroidism have been waiting for any sign that supplies of their reliable injection from Takeda might reemerge.
Last Wednesday, however, Takeda announced that supplies won’t be ready for at least another year, stranding those who still can’t access the drug, known as Natpara (parathyroid hormone), via the company’s Special Use Program (SUP), which is only for about 400 of those who are at extreme risk of life-threatening complications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.